Hexagon | AutonomouStuff Webinar Showcases How Velodyne’s Velarray H800 and PAEB Solution Can Power Advanced Driver Assistance Systems (ADAS) and Autonomy
8.12.2020 16:00:00 EET | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR) today announced Dr. Mircea Gradu, the company’s Senior Vice President of Product and Quality, is the featured speaker at a Hexagon | AutonomouStuff webinar on how lidar solutions can enhance safety in consumer vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201208005231/en/
Velodyne Lidar’s Velarray H800 solid state lidar sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. (Photo: Velodyne Lidar, Inc.)
The free webinar, called “Automotive-grade solid-state lidar for ADAS and autonomy: Velodyne Velarray H800,” takes place on December 15, 2020 at 2:00 p.m. EST. It is being moderated by Nicole Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff. To register, please click here.
The webinar will focus on the Velarray H800, Velodyne’s newly launched solid state lidar sensor designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The Velarray H800 is a key technology that will be used in systems for powerful vehicle safety, including for Automatic Emergency Braking, Lane Keep Assist and Adaptive Cruise Control.
The webinar will also cover Velodyne’s Pedestrian Automated Emergency Braking (PAEB) solution, which combines proprietary software, called Vella™, with Velodyne’s lidar sensors. Recent pedestrian crash statistics highlight an opportunity for PAEB systems to save thousands of lives annually by improving performance in dark conditions. According to the National Highway Traffic Safety Association, in 2018, 76% of the 6,283 total pedestrian crash fatalities in the U.S. occurred in dark conditions. Adding lidar can help address the risks that current PAEB systems present in frequently failing to protect pedestrians in dark conditions.
To demonstrate how PAEB systems can be achieved by utilizing lidar, Velodyne tested its lidar-based PAEB system against a highly-rated PAEB system built around camera and radar. In these nighttime conditions, the camera and radar-based PAEB system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested. The combination of Velarray lidar data and Vella processing software dramatically improves PAEB performance, addressing a use case that causes thousands of pedestrian fatalities annually, and strengthening the vehicle’s functional safety achievements. For more information on the testing, please see Velodyne’s recently issued white paper regarding PAEB here.
“Lidar is an essential building block in creating advanced driving systems that improve vehicle, passenger and pedestrian safety. Webinar attendees can hear from a leading industry authority on how the Velarray H800 lidar sensor can help make cars and roadways safer for everyone,” said Waier, Vice President, Worldwide Sales and Business Development, AutonomouStuff.
“This webinar will discuss how automakers can significantly improve effectiveness and efficiency of vehicle driver-assist features and full autonomy by employing the Velarray H800. The sensor provides a revolutionary approach to making vehicles smarter and safer,” said Gradu.
Gradu leads Velodyne’s efforts to design, develop and manufacture world-class products compliant with international quality standards and is the 2018 President and Chairman of the Board of the Society of Automotive Engineers (SAE) International. He also is a Professor in the Mechanical and Aerospace Engineering Department at University of California Irvine (UCI), a member of UCI’s Institute for Transportation Studies Leadership Council and a FISITA Council member (International Federation of the Automotive Engineering Societies).
The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in ADAS and autonomy, from Level 2 to Level 5. The sensor’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. It is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA).
About Velodyne Lidar
Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; uncertainties related to Velodyne's estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; Velodyne's ability to identify and integrate acquisitions; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201208005231/en/
Contact information
Landis Communications Inc.
Sean Dowdall
(415) 286-7121
velodyne@landispr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 14:33:00 EEST | Press release
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simultaneously building a robust pipeline of next-generation programs in AI-guided neuromodulation and min
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 14:24:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: "While the median age of diagnosis for CLL is 70 and the average age of treatment initiation is 75, many pivotal trials still underrepresent the patients that physicians most often see in practice. These data show that the durable benefit of
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 14:00:00 EEST | Press release
Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction. GreensLedge Capital Markets advised the seller. About Clearlake Clearlake Capital is a leading global alternative a
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 14:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrated statistical superiority over deucravacitinib for all key secondary endpoints, including PASI 90 response and Static Physician's Global Assessment (sPGA) 0 at week 16. Zasocitinib was generally well tolerated with a consistent safety and tolerability profile and no new safety signals identified. Perspectives on head-to-head zasocitinib study “In this head-to-head study, zasocitinib clearly demonstrated
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 13:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reliability, operational efficiency and sustainability performance. The partnership brings together LTTS’ expertise in forward looking technologies and extensive experience ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
